-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $200

Benzinga·12/15/2025 18:12:19
Listen to the news
HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $190 to $200.